Indivior Pharmaceuticals (INDV) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Indivior Pharmaceuticals (INDV) do?
Indivior Pharmaceuticals Inc (INDV) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Manufactures prescription treatments for substance use disorders and central nervous system conditions. Formulates and distributes long-acting injectable and sublingual medications treating opioid use disorder and CNS. It is worth $6.07B on the market and sold $1.38B over the last year.
- Market cap
- $6.07B
- P/E ratio
- 7.8×
- Annual sales
- $1.38B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Brief updated
- Nov 06, 2026
Brands and businesses behind INDV
- Sublocade: Monthly extended-release buprenorphine injection that earns revenue from specialty distributor and clinic orders.
- Suboxone: Sublingual film combining buprenorphine and naloxone earning revenue through retail pharmacy fills for opioid dependence.
- Opvee: Nalmefene nasal spray generating sales from emergency medical services and law enforcement overdose response programs.
- Perseris: Once-monthly subcutaneous injection generating sales from schizophrenia maintenance treatments prescribed by psychiatrists.
INDV’s flags, in plain English
Each flag is a number from Indivior Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 06, 2026.
Fat Margins
Profit margin of 32.8%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.
Wide Gross Margin
Gross margin of 85.1% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Growth vs Price
The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.
Runway Is Short
This year's bills are bigger than the cash and assets on hand to pay them. At its current rate of spending, its cash on hand covers only a limited stretch.
2 more green flags open with the free trial. Try it free for 7 days.
Questions about INDV
How big is Indivior Pharmaceuticals?
Indivior Pharmaceuticals’ market cap is $6.07B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $1.38B: what customers paid the company over the last year, before any costs.
What is INDV’s P/E ratio?
INDV’s P/E ratio is 7.8×. Investors pay about 7.8 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with INDV?
State Medicaid budget cutbacks and shifting reimbursement formulas restrict patient coverage for premium injectable therapies. That is one risk on Indivior Pharmaceuticals’ card. Its first risk flag is Runway Is Short, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Indivior Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. INDV’s filings on SEC.gov. The Margin Monkey is research, not advice.
